{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Exenatide+2+MG", "query": { "intervention": "Exenatide 2 MG" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 62, "total_pages": 7, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Exenatide+2+MG&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-11T22:56:51.468Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02975297", "title": "Exenatide Once Weekly for Smoking Cessation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Smoking Cessation" ], "interventions": [ { "name": "Exenatide", "type": "DRUG" }, { "name": "NRT", "type": "DRUG" }, { "name": "Counseling", "type": "BEHAVIORAL" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BEHAVIORAL" ], "sponsor": "The University of Texas Health Science Center, Houston", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 84, "start_date": "2016-07", "completion_date": "2020-01-03", "has_results": true, "last_update_posted_date": "2021-01-28", "last_synced_at": "2026-09-11T22:56:51.468Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02975297" }, { "nct_id": "NCT00566813", "title": "Islet Transplantation in Type 1 Diabetic Patients Using the Edmonton Protocol of Steroid Free Immunosuppression", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Diabetes Mellitus, Type 1" ], "interventions": [ { "name": "Islet Cell Transplant", "type": "DRUG" }, { "name": "Islet Cell Transplant plus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Illinois at Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 10, "start_date": "2004-11", "completion_date": "2020-07-15", "has_results": true, "last_update_posted_date": "2021-04-06", "last_synced_at": "2026-09-11T22:56:51.468Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00566813" }, { "nct_id": "NCT02802514", "title": "A Study Comparing the Effect of Albiglutide With Exenatide on Regional Brain Activity Related to Nausea in Healthy Subjects", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Diabetes Mellitus" ], "interventions": [ { "name": "Albiglutide 50mg", "type": "DRUG" }, { "name": "Albiglutide matching placebo", "type": "DRUG" }, { "name": "Exenatide 10microgram", "type": "DRUG" }, { "name": "Exenatide placebo (saline)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 5, "start_date": "2016-09-20", "completion_date": "2017-09-07", "has_results": true, "last_update_posted_date": "2020-10-30", "last_synced_at": "2026-09-11T22:56:51.468Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02802514" }, { "nct_id": "NCT00518882", "title": "Effect of Liraglutide or Exenatide Added to an Ongoing Treatment on Blood Glucose Control in Subjects With Type 2 Diabetes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes", "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "liraglutide", "type": "DRUG" }, { "name": "exenatide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novo Nordisk A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 467, "start_date": "2007-08", "completion_date": "2009-04", "has_results": true, "last_update_posted_date": "2017-03-08", "last_synced_at": "2026-09-11T22:56:51.468Z", "location_count": 61, "location_summary": "Birmingham, Alabama • Goodyear, Arizona • Artesia, California + 54 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Goodyear", "state": "Arizona" }, { "city": "Artesia", "state": "California" }, { "city": "Encino", "state": "California" }, { "city": "Escondido", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00518882" }, { "nct_id": "NCT02229396", "title": "Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes Mellitus" ], "interventions": [ { "name": "Exantide with Dapagliflozin", "type": "DRUG" }, { "name": "Exentide", "type": "DRUG" }, { "name": "Dapagliflozin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 695, "start_date": "2014-09-04", "completion_date": "2017-12-28", "has_results": true, "last_update_posted_date": "2018-12-31", "last_synced_at": "2026-09-11T22:56:51.468Z", "location_count": 76, "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Tuscumbia, Alabama + 61 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Tuscumbia", "state": "Alabama" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Tempe", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT02229396" }, { "nct_id": "NCT01455909", "title": "A Study to Evaluate ITCA 650 Compared to Sitagliptin for the Treatment of Type 2 Diabetes", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Type 2 Diabetes" ], "interventions": [ { "name": "ITCA 650 60 mcg/day", "type": "DRUG" }, { "name": "sitagliptin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Intarcia Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 0, "start_date": "2013-02", "completion_date": "2014-07", "has_results": false, "last_update_posted_date": "2012-12-25", "last_synced_at": "2026-09-11T22:56:51.468Z", "location_count": 1, "location_summary": "Hayward, California", "locations": [ { "city": "Hayward", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01455909" }, { "nct_id": "NCT02685852", "title": "Evaluating Exenatide for the Treatment of Postprandial Hyperinsulinemic Hypoglycemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hyperinsulinemic Hypoglycemia" ], "interventions": [ { "name": "Exenatide", "type": "DRUG" }, { "name": "Acarbose", "type": "DRUG" }, { "name": "Exenatide Placebo", "type": "DRUG" }, { "name": "Acarbose Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 11, "start_date": "2016-02", "completion_date": "2019-07-22", "has_results": false, "last_update_posted_date": "2021-05-06", "last_synced_at": "2026-09-11T22:56:51.468Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT02685852" }, { "nct_id": "NCT01297062", "title": "A Safety Study to Assess the Effects of Therapeutic and Supratherapeutic Exenatide Concentrations on QT Interval in Healthy Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Subjects" ], "interventions": [ { "name": "Exenatide", "type": "DRUG" }, { "name": "Moxifloxacin", "type": "DRUG" }, { "name": "Placebo comparator", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 94, "start_date": "2011-02", "completion_date": "2011-05", "has_results": true, "last_update_posted_date": "2015-04-14", "last_synced_at": "2026-09-11T22:56:51.468Z", "location_count": 2, "location_summary": "Daytona Beach, Florida • Evansville, Indiana", "locations": [ { "city": "Daytona Beach", "state": "Florida" }, { "city": "Evansville", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT01297062" }, { "nct_id": "NCT01104701", "title": "A Study to Examine the Efficacy, Safety and Tolerability, and Pharmacokinetics of Exenatide Once Monthly Suspension", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Type 2 Diabetes" ], "interventions": [ { "name": "exenatide once weekly", "type": "DRUG" }, { "name": "exenatide once monthly suspension", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 121, "start_date": "2010-05", "completion_date": "2010-12", "has_results": true, "last_update_posted_date": "2015-08-20", "last_synced_at": "2026-09-11T22:56:51.468Z", "location_count": 2, "location_summary": "Phoenix, Arizona • Lincoln, Nebraska", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Lincoln", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT01104701" }, { "nct_id": "NCT01144338", "title": "Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Type 2 Diabetes Mellitus" ], "interventions": [ { "name": "Exenatide Once Weekly", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 14752, "start_date": "2010-06-18", "completion_date": "2017-04-24", "has_results": true, "last_update_posted_date": "2018-08-08", "last_synced_at": "2026-09-11T22:56:51.468Z", "location_count": 139, "location_summary": "Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 124 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01144338" } ] }